Interview: Oryzon Chief Highlights CNS Opportunities
After the setback of Roche pulling the plug on a potentially lucrative cancer partnership last year, the Spanish biotech tells Scrip it has bounced back with a compound that shows potential in Alzheimer's, multiple sclerosis and other neurodegenerative and psychiatric diseases.
You may also be interested in...
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.
Start-ups in Spain will descend on the Andalusian city next week for the BioSpain meeting in search of national and international investors and collaborators to boost their respective R&D pipelines.
In the absence of head-to-head data, the results from a "matching-adjusted indirect comparison" suggest favorable efficacy of the German group's treatment for solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion when compared with competitor Rozlytrek from Roche.